ClinicalTrials.gg
RecruitingNCT06182072Updated Oct 1, 2025

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

A Phase 1 interventional study of ProAgio Dose Levels (DL) 1,2,3,4 and Gemcitabine, nab paclitaxel in Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by ProDa BioTech, LLC. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by ProDa BioTech, LLC · Phase 1, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine, nab-paclitaxel (G-nP) or gemcitabine, nab-paclitaxel (G-nP) and atezolizumab in previously untreated subjects with metastatic pancreatic ductal adenocarcinoma (PDAC)

Read the detailed description

This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine, nab-paclitaxel (G-nP) or gemcitabine, nab-paclitaxel (G-nP) and atezolizumab in previously untreated subjects with metastatic PDAC. The study will use an EWOC design in Phase I to determine the recommended RP2D of ProAgio with gemcitabine, nab paclitaxel (G-nP) and atezolizumab. After the estimation of RP2D of ProAgio alone, the trial will continue to estimate the RP2D of ProAgio when combined with G-nP, starting from 2 dose levels lower than the estimated RP2D of ProAgio alone. EWOC design will enroll 2 subjects per cohort with 4 combination dose levels.

Subjects will be selected based on following criteria: previously untreated advanced PDAC, ECOG performance status (0-1), and adequate organ functions. Subjects with recent surgeries, history of recent thromboembolic events or significant cardiovascular disease will be excluded.

Once the MTD and RP2D of ProAgio with G-nP RP2D have been identified, an expansion cohort of 12 subjects with metastatic PDAC (n=6 receiving ProAgio and n=6 receiving ProAgio + GnP) will begin. The purpose of the expansion cohort is to confirm the safety of the regimen and provide preliminary data on the activity of both ProAgio monotherapy and ProAgio + GnP. An additional expansion cohort with ProAgio, GnP and atezolizumab will enroll patients with metastatic PDAC (n=18 including 6 patients safety run-in). The purpose of the expansion cohort is to confirm the safety of the regimen and provide preliminary data on the activity of and ProAgio, GnP and atezolizumab combination.

Data regarding adverse events will be collected, attributed and graded according to NCI CTCAE version 5.0 criteria. Pharmacokinetic and pharmacodynamic data will be collected per the study flow chart. Response will be evaluated every 2 months using RECIST criteria. Planned secondary analyses will include ORR, duration of response, PFS and OS.

02

Conditions studied

  • Pancreatic Ductal Adenocarcinoma (PDAC)
03

In context

Lead sponsor

ProDa BioTech, LLC is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be ≥ 18 years of age on day of signing .
  2. Histologic or cytologic diagnosis of pancreatic adenocarcinoma with clinical stage IV.
  3. In the dose escalation phase: patients must be eligible for gemcitabine and nab paclitaxel. For dose expansion phase: patients must have received 5FU-based therapy for disease or for /adjuvant therapy in prior 12 months.
  4. Presence of a lesion that can be safely biopsied for correlative assays.
  5. Patient must meet the following laboratory values at the screening visit:

    • ≥1.5 x 10'9/L
    • ≥100 x 10'9/L
    • (Hgb) ≥9 g/dL
    • Serum creatinine \<1.5 mg/dL OR ≥60 mL/min using Cockcroft-Gault formula
    • Total ≤1.5 x
    • (AST) ≤2.5 x ULN, except for subjects with liver metastasis, who may only be included if AST ≤5.0 x ULN
    • Alanine transaminase (ALT) ≤2.5 x ULN, except for subjects with liver metastasis, who may only be included if ALT ≤5.0 x ULN
  6. Presence of by 1.1 criteria
  7. Patient has an (ECOG) performance status 0-1.
  8. Written informed consent must be obtained prior to any screening procedures.
  9. Normal defined as the following: at screening \<450 ms (male subjects), \<460 ms (female subjects)
  10. Before enrollment, a woman must be either:

    1. Not of : (>45 years of age with amenorrhea for at least 12 months or any age with amenorrhea for at least 6 months and a serum follicle stimulating hormone (FSH) level >40 IU/mL); permanently sterilized (eg, tubal occlusion, hysterectomy, bilateral salpingectomy); or otherwise be incapable of pregnancy.
    2. Of childbearing potential and practicing (during the study and for 6 months after receiving the last dose of study agent) a highly effective method of consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies: eg, established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device (IUD) or intrauterine system (IUS); barrier methods; true abstinence (when this is in line with the preferred and usual lifestyle of the subject).
    3. Note: If the childbearing potential changes after start of the study (eg, woman who is not heterosexually active becomes active) a woman must begin a highly effective method of birth control, as described above.
  11. A woman of childbearing potential must have a negative serum (β-human chorionic gonadotropin [β-hCG]) or urine pregnancy test at screening.
  12. During the study and for 6 months after receiving the last dose of study agent, a woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction.
  13. A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control eg, either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 3 months after receiving the last dose of study drug.
  14. Sign an informed consent document indicating that they understand the purpose of and procedures required for the study, are willing to participate in the study, and are willing and able to adhere to the prohibitions and restrictions specified in this protocol. Informed consent must be obtained before performing any study specific procedures.

Exclusion criteria

Exclusion Criteria:

  1. Prior exposure to gemcitabine and nab paclitaxel
  2. peripheral neuropathy
  3. Any untreated central nervous system (CNS) lesion. However, subjects are eligible if:

    a) all known CNS lesions have been treated with radiotherapy or surgery and b) patient remained without evidence of CNS disease progression ≥4 weeks after treatment.

  4. Use of hematopoietic colony-stimulating growth factors (eg, G-CSF, GMCSF, M-CSF), thrombopoietin mimetics or erythroid stimulating agents ≤ 2 weeks prior start of study treatment. If erythroid stimulating agents were initiated more than 2 weeks prior to the first dose of study treatment and the patient is on a stable dose, they can be maintained.
  5. Active unstable disease. Documented history of autoimmune disease that is well controlled on stable immune suppressive therapy can be enrolled after discussion with principal investigator.
  6. Allogenic bone marrow or solid organ transplant.
  7. Known history or current interstitial lung disease or non-infectious pneumonitis.
  8. Malignant disease, other than that being treated in this study. Exceptions to this exclusion include the following: that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers and any completely resected carcinoma in situ.
  9. Clinically significant infection, including known or infection, or known surface antigen positivity. Testing of asymptomatic patients will not be required.
  10. Clinically significant ongoing infection.
  11. Received an drug (including investigational vaccines) or used an invasive investigational medical device within 14 days or 5 half-lives before enrollment or is currently enrolled in the treatment stage of an investigational study.
  12. A woman who is pregnant or breast-feeding, or a woman who is planning to become pregnant or a man who plans to father a child while enrolled in this study or within 30 days after the last dose of study agent.
  13. Had hospitalization for infection or major surgery (eg, requiring general anesthesia) within 2 weeks before enrollment or have not fully recovered from surgery. Note: subjects with surgical procedures conducted under local anesthesia may participate.
  14. History or current diagnosis of cardiac disease indicating significant risk of safety for subjects participating in the study such as uncontrolled or significant cardiac disease, including any of the following:

    1. recent myocardial infarction (within last 6 months),
    2. uncontrolled congestive heart failure,
    3. unstable angina (within last 6 months),
    4. clinically significant (symptomatic) cardiac arrhythmias (e.g., sustained ventricular tachycardia, and clinically significant second or third degree AV block without a pacemaker).

    Following additional exclusion criteria applies only to the patients in the cohort including atezolizumab:

  15. Active or prior documented autoimmune or inflammatory disorders (including, but not limited to inflammatory bowel disease [e.g., colitis or Crohn's disease], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:

    • Patients with vitiligo or alopecia
    • Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
    • Any chronic skin condition that does not require systemic therapy
    • Patients without active disease in the last 5 years may be included but only after consultation with the study physician
    • Patients with celiac disease controlled by diet alone
    • Patients with type I diabetes mellitus who are on an insulin regimen are eligible for the study
  16. Current or prior use of medication ≤ 14 days prior to registration.

    The following are exceptions to this criterion:

    • Intranasal, inhaled, topical , or local steroid injections (e.g., intra articular injection)
    • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent Steroids as premedication for reactions (e.g., CT scan premedication)
  17. Receipt of ≤30 days prior to registration. Note: Patients, if enrolled, should not receive live vaccine whilst on study treatment and up to 30 days after the last dose of study treatment.
  18. History of pneumonitis/interstitial lung disease
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    ProAgio Dose Levels (DL) 1,2,3,4 ProAgio combined with gemcitabine, and nab paclitaxel is administered to study participants by intravenous injections on days 1, 8, 15, 21 every 4-week Cycle, gemcitabine and nab paclitaxel on day 1, 8, 15 every 4-week cycle during the study. Other Names: ACT50, G-nP: Gemcitabine, nab-Paclitaxel

    Drug: ProAgio Dose Levels (DL) 1,2,3,4 · Drug: Gemcitabine, nab paclitaxel

  • Experimental
    Standard Arm

    In cycle 1 of dose expansion phase of the study, half of patients (n=6) will be administered ProAgio only on day 1, 8, 15, 22 every 4-week Cycle, and half of patients (n=6) will be administered gemcitabine and nab paclitaxel are administered day 1, 8, 15 every 4-week cycle. In the atezolizumab containing cohort atezolizumab will be administered day 1 of cycle 1, and then will be repeated every 3 weeks. Other Names: ACT50, G-nP: Gemcitabine and nab-Paclitaxel, atezolizumab

    Drug: ProAgio Dose Levels (DL) 1,2,3,4 · Drug: Gemcitabine, nab paclitaxel

Interventions

This study also gives AtezolizumabStudies of AtezolizumabAtezolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Determine the safety of ProAgio combined with gemcitabine and nab paclitaxel.

    Physical examination, vital signs, clinical laboratory evaluations (CBC, serum chemistry, coagulation studies, LFTs, and assessment of subject reported AEs (via CTCAE v5.0) and SAEs will be used to evaluate safety.

    Time frame: 2 Years

  2. Determine the patient's height.

    Height measured in Centimeters (cm)

    Time frame: 2 Years

  3. Determine the patient's weight.

    Weight measured in Kilograms (kg)

    Time frame: 2 Years

  4. Determine the patient's body temperature.

    Body Temperature measured in Celsius

    Time frame: 2 Years

  5. Determine the patient's Respiration Rate.

    Respiration Rate measured in times/min

    Time frame: 2 Years

  6. Determine the patient's Heart Rate.

    Heart Rate measured in beats/min

    Time frame: 2 Years

  7. Determine the patient's Systolic Blood Pressure

    Systolic Blood Pressure measured in mmHg

    Time frame: 2 Years

  8. Determine the patient's Diastolic Blood Pressure.

    Diastolic Blood Pressure measured in mmHg

    Time frame: 2 Years

  9. Determine the patient's Pulse Oximetry.

    Perform Pulse Oximetry measured in (SpO2)

    Time frame: 2 Years

  10. Determine a single ideal dose which will be selected for further investigation in the dose escalation cohort.

    Following completion of the dose escalation cohort, all available data relating to the pharmacokinetics, pharmacodynamics, efficacy and safety of ProAgio combined with gemcitabine and nab paclitaxel will be reviewed by the study team including the Principle Investigator, clinical pharmacology collaborators and the sponsor. A single ideal dose will then be selected for further investigation in the dose escalation cohort. This ideal dose may or may not be the same as the MTD.

    Time frame: 2 Years

Secondary outcomes

  1. Determine the total integrated area under the plasma drug concentration-time curve (AUC).

    Analyze pharmacokinetics to determine the total integrated area under the plasma drug concentration-time curve (AUC).

    Time frame: 2 Years

  2. Determine the Peak Plasma Concentration (Cmax).

    Pharmacokinetics will be analyzed by determining Peak Plasma Concentration (Cmax).

    Time frame: 2 Years

  3. Determine how well the patient eliminates the study drug (CL).

    Pharmacokinetics will be analyzed by determining how well the patient eliminates the drug (CL).

    Time frame: 2 Years

  4. Determine Volume of distribution (Vd).

    Pharmacokinetics will be analyzed by determining Volume of distribution (Vd).

    Time frame: 2 Years

  5. Determine the study drug half-life (t1/2).

    Pharmacokinetics will be analyzed by determining the study drug half-life (t1/2).

    Time frame: 2 Years

  6. An attempt will be made to determine dose proportionality of ProAgio.

    Pharmacokinetics will be analyzed by determining the amount of drug reaching the systemic circulation.

    Time frame: 2 Years

  7. Evaluate Objective response rate (ORR).

    Objective response rate (ORR), defined as complete response (CR) or partial response (PR) through cycle 6 per RECIST 1.1 as a proportion of n=6 of the Phase1b cohorts.

    Time frame: 2 Years

  8. Evaluate Duration of response (DOR).

    Duration of response (DOR), determined from date of best response to progression or death.

    Time frame: 2 Years

  9. Evaluate Progression-free Survival (PFS).

    Progression-free Survival (PFS), determined from date of 1st dose of study drug to progression or death.

    Time frame: 2 Years

  10. Evaluate Overall Survival (OS).

    Overall Survival (OS) determined from date of 1st dose of study drug to death from any cause. CA19-9 will be assessed by descriptive statistics.

    Time frame: 2 Years

  11. Evaluate patient tumor response.

    MR imaging assessment of patient tumor response using a unique MRI photon to monitor tumor changes and tumor blood perfusion changes.

    Time frame: 2 Years

Other outcomes

  1. Evaluate patient Pyruvate kinase-M2 (PKM2).

    Descriptive statistics will be used to summarize the expression of PKM2 in each batch of blood samples collected from subjects at pre-treatment, 48 hrs, and 14 days post-treatment, respectively.

    Time frame: 2 Years

  2. Evaluate tumor biology changes due to treatment.

    Descriptive statistics will be used to summarize the desmoplastic stroma, intratumoral collagen, blood vessels, CAPSC, and αvβ3 expression in each batch of biopsy samples taken from subjects at pre-treatment and 4 weeks post-treatment, respectively.

    Time frame: 2 Years

  3. Evaluate patient tumor fibrosis pre and post treatment with ProAgio.

    Perfusion MRI will be performed pre and on treatment with ProAgio to assess impact on fibrosis.

    Time frame: 2 Years

  4. Evaluate patient monitor tumor angiogenesis pre and post treatment with ProAgio.

    Perfusion MRI will be performed pre and on treatment with ProAgio to assess impact on angiogenesis.

    Time frame: 2 Years

  5. Evaluate patient tumor blood perfusion pre and post treatment with ProAgio.

    Perfusion MRI will be performed pre and on treatment with ProAgio to assess impact on perfusion.

    Time frame: 2 Years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bandi DSR, Sarvesh S, Nagaraju GP, Kim H, Foote J, Bae S, Yoon KJ, Malla M, Masood A, Akce M, Liu ZR, El-Rayes BF. ProAgio, a Novel Integrin alphavbeta3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment. bioRxiv [Preprint]. 2026 Jan 16:2026.01.15.699725. doi: 10.64898/2026.01.15.699725. PubMed 41648362 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Jun 2027, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2023
First posted
Dec 26, 2023
StartActual
Sep 14, 2023
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06182072
Lead sponsor
ProDa BioTech, LLC
Collaborators
University of Alabama at Birmingham, Georgia State University
Responsible party
Sponsor
First posted
Dec 26, 2023
Start date
Sep 14, 2023
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Oct 1, 2025

Study contacts

Damon R Michaels
Contact
damon.michaels@medelis.com
615-614-1185
Zhi-Ren Lui
Contact
zliu8@gsu.edu
Mehmet Akce, MD
principal investigator · The University of Alabama at Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion